AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$AMLX

FRATES JAMES M sold $350K of AMLX

FRATES JAMES M (Chief Financial Officer) sold 10,810 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.36 ($32.27–$33.23, $0.35M total) across 2 trades on 2026-09-10.

Original reporting
SEC EDGAR · FRATES JAMES M
Published Sep 14, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AMLX
Bearish
medium confidence
Mentioned
$AMLX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMLXBearishLow
01

Why it matters

The CFO's discretionary sale of roughly $350K may prompt short‑term scrutiny but is unlikely to alter long‑term fundamentals.

02

Market read

Primary insider filing with modest monetary value; limited trading relevance.

03

What to watch

CFO may be diversifying holdings; no 10b5‑1 plan indicates discretionary decision.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑10

Background

Amylyx Pharmaceuticals (AMLX) is a biotech focused on neurodegenerative disease therapies.

Company-level read

Ticker impact

$AMLXBearishMedium confidence
Context

Chief Financial Officer sold 10,810 shares for $349,821 on 2026-09-10, reducing his stake to 233,625 shares.

Expected impact

Possible short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

Sale size is modest relative to market cap, but CFO insider sales often attract attention; no 10b5‑1 plan suggests discretionary timing.

Market effects

Sector

Limited impact on biotech sector; similar insider sales are common.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Officer
    FRATES JAMES M

    Chief Financial Officer of Amylyx Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMLX insider trading history →

Related articles

OCT 3
$AMLXLowAI 8/10

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals reported positive Phase III results for avexitide in treating PBH, with plans to file for FDA approval by year-end. The company estimates 160,000 U.S. patients with PBH, with 120,000 following Roux-en-Y gastric bypass. Management is preparing for a potential 2024 or 2027 launch, depending on the FDA label. Amylyx is also developing AMX0318 for PBH, targeting an IND filing next year.

finance.yahoo.com2 min
SEP 18
$AMLXHighAI 8/10

Amylyx Stock Tumbles As Rally Meets Dilution Jitters

Amylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.

tipranks.com2 min
SEP 12
$AMLXHigh

Why Is AMLX Stock Popping 14% After Hours?

Amylyx Pharmaceuticals (AMLX) shares rose 14% after-hours as it prepares to release Phase 3 trial results for avexitide, its lead drug candidate for post-bariatric hypoglycemia. The trial's success could support a 2027 regulatory filing. AMLX has no FDA-approved therapies currently, and its cash runway extends into 2028. Mizuho raised its price target to $30, citing potential launch pricing updates.

stocktwits.com1 min
SEP 1
$AMLXMedAI 8/10

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals (AMLX) has surged 247% this year after positive trial results for its experimental treatment, avexitide, which met all endpoints. The company aims to submit avexitide for FDA approval by year-end, with analysts estimating $1.5B in peak U.S. sales. Amylyx recently raised $500M through a stock offering. The stock is trading at $34.74, with a market cap of $4.2B.

fool.com2 min
SEP 1
$AMLXHighAI 8/10

1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals (AMLX) raised $500M, strengthening its balance sheet. Its experimental drug, avexitide, reduced serious hypoglycemic events by 55% in a phase 3 trial, with potential FDA submission by year-end. Analysts estimate peak U.S. sales at $1.5B. The stock has surged 247% year-to-date, but analysts suggest a pullback to $28-$30 per share for better entry.

aol.com2 min